Exogen Medicare Coverage Reconsideration Attracts Physician Support
This article was originally published in The Gray Sheet
Executive Summary
Unrestricted national coverage for Smith & Nephew's Exogen ultrasonic bone growth stimulator is warranted due to potential cost savings, high patient compatibility and shorter treatment times compared to surgery, practitioners and patients tell CMS
You may also be interested in...
CMS Proposes Non-Coverage For S&N Exogen For Nonunion Fracture Healing
CMS is continuing its recent trend of promoting clinical trial coverage by proposing to extend reimbursement for Smith & Nephew's Exogen ultrasound bone growth stimulator for nonunion fracture healing for recipients enrolled in a qualifying trial
CMS Proposes Non-Coverage For S&N Exogen For Nonunion Fracture Healing
CMS is continuing its recent trend of promoting clinical trial coverage by proposing to extend reimbursement for Smith & Nephew's Exogen ultrasound bone growth stimulator for nonunion fracture healing for recipients enrolled in a qualifying trial
Ultrasonic stimulation NCD
Smith & Nephew (Exogen bone growth stimulator) convinces CMS to reconsider its national coverage decision for ultrasound stimulation for nonunion fracture healing. The stimulators currently are covered for treating nonunion fractures, except for the skull, vertebrae and tumor-related nonunions. By contrast, the agency has a national non-coverage policy in place for fresh fractures and delayed unions. CMS expects to issue a decision by April 22...